AC
SNTI icon

Armistice Capital’s Senti Biosciences Holdings SNTI Stock Holding History

Armistice Capital’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-892,207
Closed -$1.88M – 386
2025
Q2 		$1.88M Buy
+892,207
New +$2.82M 0.03% 135

Other funds holding SNTI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
8GI
8VC GP I Austin, Texas $39.6M AUM 36.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Armistice Capital's SNTI Position: Q3 2025 in Review

Armistice Capital sold out of Senti Biosciences Holdings (SNTI) in Q3 2025, closing a stake of 892,207 shares — an estimated $1.88M sold.

Armistice Capital first reported a position in SNTI in Q2 2025 and held it in 1 quarter. The position peaked at $1.88M in Q2 2025. 16 funds tracked by Wall St. Rank hold SNTI as of Q3 2025.

  • Armistice Capital reported no remaining Senti Biosciences Holdings position as of Q3 2025 after selling out during the quarter.
  • Armistice Capital sold 892,207 Senti Biosciences Holdings shares in Q3 2025, an estimated $1.88M.
  • Armistice Capital first reported a position in Senti Biosciences Holdings in Q2 2025 and held it in 1 quarter.
  • Armistice Capital's Senti Biosciences Holdings position peaked at $1.88M in Q2 2025.
  • 16 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.